Home
Joel Mayer's Purgatory Mac OS

Joel Mayer's Purgatory Mac OS

May 09 2021

Joel Mayer's Purgatory Mac OS

View Joel Salinas’ profile on LinkedIn, the world's largest professional community. Joel has 3 jobs listed on their profile. See the complete profile on LinkedIn and discover Joel’s. CinePiano is the modern follow-up to our popular Piano in Blue library. Sampled by hand at the MGM Scoring Stage at Sony Pictures Studios in Los Angeles, we applied the same recording and sampling techniques and many of the same microphones from Piano in Blue. With four distinct sonic characters, CinePiano will be your most versatile piano library. For Joel Mayer's Purgatory on the Macintosh, GameFAQs has game information and a community message board for game discussion. Venmo is a digital wallet that makes money easier for everyone from students to small businesses. More than 60 million people use the Venmo app for fast, safe, social payments.

Home >Courses > AASLD/IDSA Guidelines: Recommendations for Testing, Managing, and Treating HCV
Sorry, this learning module is not available for mobile devices.

Review Date: 9/15/2015

The enduring material is jointly provided by William Beaumont Hospital, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV).

The 9th Annual American Conference for the Treatment of HIV (ACTHIV) was held April 30-May 2, 2015 in Dallas, TX. The Conference was supported by funding from the Office of AIDS Research of the National Institutes of Health; Clinical Education Initiative, New York State Department of Health, AIDS Institute; and from the HIV Medicine Association (HIVMA). The conference and this web archive were supported by educational grants from AbbVie, Gilead Sciences, Janssen Therapeutics, Merck & Co., and ViiV Healthcare.

ONLINE CE CREDIT:

To obtain online CE credit, please follow this link to the course post-test quiz and follow the instructions.

FACULTY:
Jay R. Kostman, MD is Clinical Professor of Medicine and Associate Director, Center for Viral Hepatitis at the Perelman School of Medicine, University of Pennsylvania.

Estimated time to complete: 30 minutes

Joel Mayer's Purgatory Mac Os X

TARGET AUDIENCE
Physicians (both specialists and primary care/family medicine), nurse practitioners, and nurses who are frontline providers of care to persons at risk of or with HIV infection. Physician assistants, pharmacists, case managers and other healthcare professionals may also participate.

Learning Objectives
As a result of participating in this activity, participants should be better able to:

  • Review current recommendations for testing and linkage to care
  • Describe current recommendations on HCV treatment prioritization
  • State which regimens are recommended for HCV treatment by genotype, treatment experience, and stage of liver disease
  • Describe recommendations for monitoring before and during treatment

ACCREDITATION

Physicians:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of William Beaumont Hospital, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV). William Beaumont Hospital is accredited by the ACCME to provide continuing medical education for physicians.

William Beaumont Hospital designates this enduring material for a maximum of 0.5 AMA PRA Category 1
Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Nurse Practitioners:

American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

American Academy of CME, Inc. designates this educational activity for 0.5 contact hours (0.5 pharmacotherapeutic contact hours).

Physician Assistants:

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hours of Category 1 credit for completing this program.

There is no fee to participate in this activity.

HOW TO RECEIVE CREDIT

In order to obtain your certificate of credit, you must:

  • read the CME/CE information and review the full content of the activity
  • achieve a passing grade on the post-test (75% or greater), and
  • complete the evaluation.

Your certificate for the activity will be made available immediately to print online.

Purgatory

DISCLOSURES

According to the disclosure policy of Academy and Beaumont, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures will be made known to the participants prior to the activity.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, Beaumont, ACTHIV or the American Nurses Credentialing Council’s Commission on Accreditation. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Off-Label Usage Disclosure

This activity does not contain off-label discussion.

Faculty Disclosure

Jay Kostman, MD - Advisory Board: AbbVie, Gilead Sciences; Grant Recipient / Research Support: Gilead Sciences

Joel Mayer's Purgatory Mac Os 7

Planner Disclosures

The following planners have indicated they have no relevant financial relationships to disclose: Bruce D. Agins, MD, MPH; John T. Brooks, MD, Monica Gandhi, MD, MPH, Christopher Gordon, PhD; John JD Juchniewicz, MCIS, CHCP; Natalie Kirkwood, RN, BSN, JD; Harry Lampiris, MD, Edward Moylan, RP; Tonia Poteat, PhD, MPH, PA-C, Asa Radix, MD, MPH, Renslow Sherer, MD; Cheryl Smith, MD; Brooke J. Taylor, MPH, CHCP; Ronald Dean Wilcox, MD; Barbara A. Young, MSW, LCSE, LCADC, SAC

Joel Mayer's Purgatory Mac Os Catalina

The following planners have indicated they have relevant financial relationships to disclose:

Laura Armas-Kolostroubis, MD - Advisory Board: Gilead Sciences
Roger Bedimo, MD, MS - Advisory Board: Merck & Co.; Grant Recipient / Research Support: Merck & Co., Bristol-Myers Squibb
Elizabeth Connick, MD - Shareholder: Pfizer
Carlos del Rio, MD - Board Member: HIVMA, IAS-USA
Donna Futterman, MD - Grant Recipient / Research Support: Gilead Sciences
Joel Gallant, MD, MPH - Advisory Boards: Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co.; Consultant: Takara Bio Grant Recipient / Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck & Co., Sangamo BioSciences, Vertex Pharmaceuticals, ViiV Healthcare
Rajesh Gandhi, MD - Grant Recipient / Research Support: Gilead Sciences, Janssen Therapeutics, Roche, ViiV Healthcare
Peter Hunt, MD - Advisory Board: Merck & Co.; Consultant: Bristol-Myers Squibb, Gilead Sciences, Merck & Co., Tobira Therapeutics; Honoraria (non-promotional lectures on immune activation): Gilead Sciences, Janssen Therapeutics
Sharon Lee, MD - Advisory Board: Gilead Sciences, ViiV Healthcare
Vincent Lo Re, MD, MSCE - Grant Recipient / Research Support: AstraZeneca, Gilead Sciences
Michael J. Mugavero, MD, MHSc - Advisory Board: Bristol-Myers Squibb, Gilead Sciences; Grant Recipient / Research Support: Bristol-Myers Squibb
William R. Short, MD, MPH - Advisory Board: Gilead Sciences, Janssen Therapeutics, ViiV Healthcare; Grant Recipient / Research Support: Gilead Sciences, Janssen Therapeutics; Promotional Speakers Bureaus: Gilead Sicences, Janssen Therapeutics
Kathleen E. Squires, MD - Advisory Board: Gilead Sciences, Janssen Therapeutics, Bristol-Myers Squibb, Merck & Co., Tobira Therapeutics, ViiV Healthcare; Consultant: Merck & Co.; Grant Recipient / Research Support: Gilead Sciences,Vertex Pharmaceuticals
Melanie Thompson, MD - Grant Recipient / Research Support: Bristol Myers Squibb, Gilead Sciences, GeoVax, Kowa Research Institute, Pfizer, Janssen/Tibotec Therapeutics, Merck & Co., Tobira Therapeutics, ViiV Healthcare; Data Safety Monitoring Boards: Janssen/Tibotec Therapeutics, ViiV Healthcare; Honorarium (for lectures): Hetero Pharmaceuticals
Andrea Weddle, MSW - Advisory Board (ACA): Janssen Therapeutics
Susan Ellen Weiss, FNP - Advisory Board: Bristol-Myers Squibb, Gilead Sciences; Consultant: Gilead Sciences; Promotional Speaker’s Bureau: Janssen Therapeutics

Privacy Policy
For more information about Beaumont privacy policy, please access http://www.beaumont.edu/privacy-policy
For more information about Academy privacy policy, please access http://www.academycme.org/privacy.htm

Joel Mayer

For CME information or credit details, contact: cme@beaumont.edu

For CNE information or credit details, contact: CEservices@academycme.org

Hardware/Software Requirements
To access this activity hardware and software requirements are noted below.
Windows Requirements: • Operating system: Windows Vista Service Pack 2 or later • Browser: Internet Explorer 9 or later, Mozilla Firefox 40 or later, Google Chrome 44 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 18 or later
Macintosh Requirements: •Operating system: Mac OS X v10.7 or later • Browser: Mozilla Firefox 40 or later, Chrome 44 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 18 or later

Copyright 2015. American Academy of CME, Inc., William Beaumont Hospital, and American Conference for the Treatment of HIV.

Bibliographic Sources:

  • AASLD/IDSA HCV Guidelines. Available at: http://www.hcvguidelines.org/
Presenter
  • Jay R. Kostman, MD
    Clinical Professor of Medicine
    Associate Director of the Viral Hepatitis Center
    University of Pennsylvania
Presenter Bio
Dr. Kostman has been the Principal Investigator on Clinical Trials in HIV/AIDS for 25 years, including in NIH sponsored clinical trials networks. He is the associate director of the Viral Hepatitis Center at the University of Pennsylvania and has extensive experience in the treatment of HIV/HCV Co-Infection, both in clinical trials and in the real world. He is also recognized as a national expert in HIV-HCV co-infection and has lectured extensively on this topic. As co-chair of the HIV-HCV Scientific Working Group of the Penn Center for AIDS Research for the last two years, Dr. Kostman has worked to develop projects including studies of the long term complications of chronic hepatitis C infection, effectiveness of HCV treatment in co-infected individuals, and virologic outcomes of hepatitis B treatment.

Joel Mayer's Purgatory Mac OS

Leave a Reply

Cancel reply